Ultimovacs downsizes to funnel funds to cancer vaccine programme
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is a trainee healthcare and pharmaceutical reporter. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
-
Portage mulls company closure, pauses enrolment for lead clinical programme
US-based Portage Biotech is cash-strapped and has started looking for strategic alternatives including a wind-down of the company. The company…
-
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…
-
OSE wins French govt grant for Phase III trial for cancer vaccine
OSE Immunotherapeutics has received €8.4m ($9m) in non-dilutive funding from the ‘France 2030’ plan funded by the French Government. The…
-
TORL scores $158m in Series B2 to advance ADC cancer therapies
TORL BioTherapeutics has raised $158m in Series B-2 financing to advance the clinical development of its lead antibody-drug conjugate (ADC),…
-
Basilea wins CARB-X grant for new antibody development
Switzerland-based Basilea Pharmaceutica has received a $0.9m grant from the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), to develop…
-
Prothea debuts with $13m to develop cancer diagnostics and treatment
The University of Edinburgh and Bath spin-off, Prothea Technologies, has closed €12m ($13m) in Series A financing to develop cancer…
-
J&J and Legend’s Carvykti scores early line approval for MM by FDA
The US Food and Drug Administration (FDA) has approved Johnson and Johnson (J&J) and Legend Biotech’s chimeric antigen receptor (CAR)-T…
-
GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include its use…